MX2021008152A - Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb. - Google Patents

Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb.

Info

Publication number
MX2021008152A
MX2021008152A MX2021008152A MX2021008152A MX2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A MX 2021008152 A MX2021008152 A MX 2021008152A
Authority
MX
Mexico
Prior art keywords
cells
polypeptide levels
methods
nucleus
materials
Prior art date
Application number
MX2021008152A
Other languages
English (en)
Inventor
Beibei Chen
Yuan Liu
Toren Finkel
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of MX2021008152A publication Critical patent/MX2021008152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Este documento proporciona métodos y materiales para aumentar los niveles del polipéptido de TFEB. Por ejemplo, se proporcionan compuestos (por ejemplo, compuestos orgánicos) que pueden aumentar los niveles del polipéptido de TFEB dentro de las células y/o dentro de un núcleo de las células, formulaciones que contienen los compuestos que pueden aumentar los niveles del polipéptido de TFEB dentro de las células y/o dentro de un núcleo de las células, métodos para preparar compuestos que pueden aumentar los niveles del polipéptido de TFEB dentro de las células y/o dentro de un núcleo de las células, métodos para preparar formulaciones que contienen compuestos que pueden aumentar los niveles del polipéptido de TFEB dentro de las células y/o dentro de un núcleo de las células, métodos para aumentar los niveles del polipéptido de TFEB dentro de las células y/o dentro de un núcleo de las células y métodos para tratar mamíferos (por ejemplo, seres humanos) que tienen una afección que responde a un aumento de los niveles del polipéptido de TFEB.
MX2021008152A 2019-01-03 2020-01-03 Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb. MX2021008152A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788049P 2019-01-03 2019-01-03
US201962879374P 2019-07-26 2019-07-26
PCT/US2020/012268 WO2020142748A1 (en) 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels

Publications (1)

Publication Number Publication Date
MX2021008152A true MX2021008152A (es) 2021-10-13

Family

ID=71406977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008152A MX2021008152A (es) 2019-01-03 2020-01-03 Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb.

Country Status (12)

Country Link
US (1) US20220112218A1 (es)
EP (1) EP3906033A4 (es)
JP (1) JP2022516631A (es)
KR (1) KR20210111787A (es)
CN (1) CN113316453A (es)
AU (1) AU2020204717A1 (es)
BR (1) BR112021012950A2 (es)
CA (1) CA3123902A1 (es)
IL (1) IL284403A (es)
MX (1) MX2021008152A (es)
SG (1) SG11202105685TA (es)
WO (1) WO2020142748A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE60128709T2 (de) * 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7198926B2 (en) 2003-05-08 2007-04-03 E. I. Du Pont De Nemours And Company Preparation of (E)- and (Z)-2-methyl-2-butenoic acids
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EP2324022A1 (de) * 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
US8604049B2 (en) * 2008-08-05 2013-12-10 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
GB201007203D0 (en) * 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
ES2914085T3 (es) 2014-11-19 2022-06-07 Univ Rush Medical Center Composiciones y métodos para el tratamiento de trastornos lisosomales
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
US11339144B2 (en) * 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof

Also Published As

Publication number Publication date
CN113316453A (zh) 2021-08-27
CA3123902A1 (en) 2020-07-09
SG11202105685TA (en) 2021-06-29
KR20210111787A (ko) 2021-09-13
AU2020204717A1 (en) 2021-06-10
EP3906033A1 (en) 2021-11-10
IL284403A (en) 2021-08-31
WO2020142748A1 (en) 2020-07-09
EP3906033A4 (en) 2022-11-09
US20220112218A1 (en) 2022-04-14
BR112021012950A2 (pt) 2021-09-14
JP2022516631A (ja) 2022-03-01

Similar Documents

Publication Publication Date Title
MX2021008152A (es) Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb.
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
WO2019035880A8 (en) EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
WO2018064594A3 (en) Hla class i-deficient nk-92 cells with decreased immunogenicity
WO2019089884A3 (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
NZ599174A (en) Combinations comprising a fungicidal strain and an azolopyrimidin-7-ylamine
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
EP3842515A4 (en) NOVEL STRAIN OF CUTIBACTERIUM GRANULOSUM, AND COMPOSITION COMPRISING SUCH STRAIN OR CULTURE OF SUCH STRAIN FOR PREVENTING OR TREATING ACNE
MX2015012739A (es) Composiciones y metodos para tratar la mucopolisacaridosis tipo 1.
BR112019013005A2 (pt) espécie de metschnikowia isolada, método para produzir xilitol, xilitol bioderivado e composição
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
WO2020231882A3 (en) Modified pluripotent cells
WO2018204734A8 (en) Compositions and methods for expressing otoferlin
MX2021000153A (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.
MX2020001666A (es) Biopesticidas.
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
PH12020550117A1 (en) Variant rnai
MX2022001977A (es) Poblaciones de celulas t gamma delta t ex vivo.
CL2021003043A1 (es) Método para producir una planta leñosa genéticamente modificada que tiene biomasa y/o densidad de la madera aumentadas (divisional solicitud 201701418)
PH12019501767A1 (en) Methods and micro organisms for making 2,3-butanediol and derivatives thereof from ci carbons
AR110639A1 (es) Mutantes de bacilos y métodos para su uso
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
MY191497A (en) Curable composition comprising an ethylene polymer, a monoperoxycarbonate and a t-alkyl hydroperoxide